Ticker Details
Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Inc is biotechnology company focused on the development of products for inflammation, inborn errors of metabolism, and other diseases, related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes.
IPO Date:	April 28, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$95.69M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.20 | 3.31%
Avg Daily Range (30 D):	$0.17 | 6.15%
Avg Daily Range (90 D):	$0.17 | 4.47%

Institutional Daily Volume
Avg Daily Volume:	.57M
Avg Daily Volume (30 D):	4.64M
Avg Daily Volume (90 D):	2.23M

Trade Size
Avg Trade Size (Sh.):	144
Avg Trade Size (Sh.) (30 D):	209
Avg Trade Size (Sh.) (90 D):	165

Institutional Trades
Total Institutional Trades:	448
Avg Institutional Trade:	$1.7M
Avg Institutional Trade (30 D):	$.58M
Avg Institutional Trade (90 D):	$.76M
Avg Institutional Trade Volume:	.23M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.89M
Avg Closing Trade (30 D):	$.58M
Avg Closing Trade (90 D):	$.77M
Avg Closing Volume:	254.18K

News

Apr 10, 2026 @ 6:53 PM ALDX Investors Have Opportunity to Lead Aldeyra Th... Source: The Schall Law Firm

Apr 9, 2026 @ 6:52 PM ROSEN, A LEADING AND RANKED FIRM, Encourages Aldey... Source: Rosen Law Firm

Apr 8, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Th... Source: Bronstein, Gewirtz & Grossman Llc

Apr 6, 2026 @ 8:00 PM ALDX Investor Alert: Aldeyra Therapeutics Securiti... Source: Levi & Korsinsky, Llp

Apr 6, 2026 @ 6:32 PM ADLX Class Action Notice: Robbins LLP Reminds Inve... Source: Robbins Llp

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.56	$-.1	$-.56
Diluted EPS	$-.56	$-.1	$-.56
Revenue
Gross Profit
Net Income / Loss	$-33.85M	$-6.46M	$-33.85M
Operating Income / Loss	$-35.27M	$-6.67M	$-35.27M
Cost of Revenue
Net Cash Flow	$15.51M	$10.7M	$15.51M
PE Ratio